🔻🔻Live in a few minutes ⌛️
#ClinicalTrialsMasterclass
🫀Designing trials in antiplatelet therapy, with @Drroxmehran @DjawidHashemi @aayshacader
🔗
@KardiologieHH @ANazmiCalik @mirvatalasnag @Hragy @mmamas1973 @vass_vassiliou #CardioTwitter #DAPT
Evolving duration of antiplatelet therapy #DAPT ⤵️
🔻1995 to 2020 🔻
@Drroxmehran #CardioTwitter
Balancing the bleeding 🩸and ischemic risk 🫀@Drroxmehran #CardioTwitter #DAPT
Antiplatelet therapy: what can be tested ⁉️@Drroxmehran ⤵️
@DjawidHashemi @aayshacader @KardiologieHH @mirvatalasnag @ANazmiCalik #CardioTwitter
@Drroxmehran explained possible differences between investigator-initiated trials and industry-sponsored trials. #CardioTwitter #DAPT ⤵️
🫀🩸Comparison of the #TWILIGHT Trial with other #RCT on P2Y12 monotherapy, by @Drroxmehran #CardioTwitter ⤵️⤵️
@aayshacader @DjawidHashemi @KardiologieHH @mirvatalasnag @Hragy @SABOURETCardio @mmamas1973 @ANazmiCalik @CMichaelGibson
🫀How to achieve “double-blinding” in #antiplatelet therapy #trials⁉️
The need for🔥Firewalls🔥🔐
⤵️ Great slide by @Drroxmehran about double-blind in the #TWILIGHT Trial #CardioTwitter
@mmamas1973 @DrPascalMeier @mirvatalasnag @KardiologieHH @DjawidHashemi @aayshacader
Share this Scrolly Tale with your friends.
A Scrolly Tale is a new way to read Twitter threads with a more visually immersive experience.
Discover more beautiful Scrolly Tales like this.